Numerous studies have shown that UGT1A1 plays a crucial role in the biotransformation of the chemotherapeutic drug irinotecan, which is used to treat advanced CRC and pancreatic cancer. This evidence concerns the gene UGT1A1 and colorectal carcinoma.